Valvular & structural heart disease
Valve-in-Valve TAVR for Degenerated Surgical Valves in Patients With Small Aortic Annuli: A Report From a Japanese Nationwide Registry
Authors' conclusion
ViV-TAVR for small aortic annuli in Japanese patients was associated with an increased risk of PPM; however, no differences in clinical outcomes were observed according to aortic annulus size or valve type. Due to the small size of our sample, further research is required to validate these findings.
Study context
- Population
- Patients with failed surgical bioprosthetic aortic valves undergoing valve-in-valve transcatheter aortic valve replacement (ViV-TAVR), J-TVT registry, July 2018 through December 2022final sample, among 47,800 individuals, 1029 underwent ViV-TAVR · small annulus group 225 · nonsmall group 180
- Participants
- 405 patients
- Exposure
- Small vs nonsmall aortic annulus in ViV-TAVR
- small annulus groupn = 225
- nonsmall groupn = 180
Main finding
As reported in the abstract
Indexed effective orifice area and PPM · within 30 days after ViV-TAVR
PPM rate small annulus group 59.2% · nonsmall group 44.4%
Observational data: associations, not effects.
Further findings
Indexed effective orifice area and PPM by valve type (small annuli)
PPM rate balloon-expandable valve group (n=61) 67.2% · supraannular self-expanding valve group (n=164) 56.1%
- Indexed effective orifice area and prosthesis-patient mismatch (PPM) by valve type (small annuli): among the 225 patients with small annuli
PPM associated with small annuli
- Small annuli independently associated with PPM, odds ratio (95% CI, 1.26-2.87); P =0.002
- 1.9
30-day and 1-year outcomes
- No differences between groups
Outcomes by valve type
- No differences in outcomes based on the type of valve implanted
Original publication
Summarised from the published abstract; every number is checked against it